

Human and Vertebrate Animal Tissue Form (6B)

Required for research involving fresh/frozen tissue (including primary cell lines, human and other primate established cell lines and tissue cultures), blood, blood products and body fluids. If the research involves living organisms please ensure that the proper human or animal forms are completed. **All projects using any tissue listed above must also complete Form 6A.**

Student's Name(s) GISELLE RASQUINHA

Title of Project Lipid Conjugation Yields Novel HIV-1 Fusion Inhibitor that Demonstrates Improved Efficacy and Prolonged Serum Half-life

To be completed by Student Researcher(s):

1. What vertebrate animal tissue will be used in this study? Check all that apply.
 - ☐ Fresh or frozen tissue sample
 - ☐ Fresh organ or other body part
 - ☒ Blood
 - ☐ Body fluids
 - ☐ Primary cell/tissue cultures
 - ☒ Human or other primate established cell lines
2. Where will the above tissue(s) be obtained. If using an established cell line include source and catalog number.

Blood obtained from in-house mice (not sacrificed)
MT-2 and H-9 cell lines from Sigma Chemical Co. MT-2 (Cat #08081401) H-9 (Cat #85050301)
M-7 cell lines from ATCC (Cat # CRL-2804)
3. If the tissue will be obtained from a vertebrate animal study conducted at a research institution attach a copy of the IACUC certification with the name of the research institution, the title of the study, the IACUC approval number and a of IACUC approval.

IACUC, Lindsley Kimball Research Institute, New York Blood Center
"Generation of antibodies against Structural proteins of HIV, Coronaviruses, ASFV and Influenza Virus"
IACUC Approval # 194.18/194.20

To be completed by the Qualified Scientist or Designated Supervisor:

- ☒ I verify that the student will work solely with organs, tissues, cultures or cells that will be supplied to him/her by myself or qualified personnel from the laboratory; and that if vertebrate animals were euthanized they were euthanized for a purpose other than the student's research.

AND/OR

- ☒ I certify that the blood, blood products, tissues or body fluids in this project will be handled in accordance with the standards and guidance set forth in U.S. Occupational Safety and Health Act, 29CFR, Subpart Z, 1910.1030 - Blood Borne Pathogens.

Lanying Du



July 01 2019

Printed Name

Signature

Date of Approval (mm/dd/yy)
(Must be prior to experimentation.)

Head, Department of Viral immunology


LDu@nybc.org

Title

Phone/Email


Lindsley Kimball Research Institute, New York Blood Center, NY 10065

Institution

 **New York Blood Center**
Institutional Biosafety Committee
310 East 67th Street
New York, New York 10065
212-570-3034

MEMORANDUM

TO: Lanying Du, Ph.D.
Head, Viral Immunology

FROM: John Svagr 
Biosafety Officer, Institutional Biosafety Committee

DATE: April 24, 2019

RE: **Protocol 21-SJ1-98:**
Structure, function & immunogenicity of HIV gp41 core

The above referenced protocol was presented to the IBC full board for review. Please note your protocol has been approved having met the requested modifications at the status of "BSL2". This approval is valid until the next IBC Meeting. Thank you.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE

THE NEW YORK BLOOD CENTER

310 East 67th Street, New York, NY. 10065

NYBC Project #: 194.18/194.20

Submission Date 08/13/2019

(The IACUC will assign #'s to New Protocols)

Circle one(1) category: NEW THREE YEAR ANNUAL ADDENDUM TERMINATE

Project Title: ADDENDUM Generation of antibodies against structural proteins of HIV, coronaviruses, ASFV, and influenza virus.

Grant Title: (1) Structure-Based design of coronavirus submit vaccines and (2) Rational design and evaluation of novel mRNA vaccines against ERS-CoV.

Principal Investigator: Lanying Du, PhD.

Department: Viral Immunology Extension: 3459

The Institutional Animal Care and Use Committee of the New York Blood Center have reviewed the above protocol:

Date of IACUC Review: 02/19/2019, 04/09/2019, 08/13/19

Decision: APPROVED MODIFICATIONS TO SECURE APPROVAL NOT APPROVED

Congruency Statement – Prior to receipt of an award, NIH requires institutions to ensure that all aspects of the grant involving animals are described in approved Institutional Animal Care and Use Committee (IACUC) protocols. In accordance with NIH requirements, the above referenced grant application and the corresponding IACUC protocol(s) (IACUC ID) was (were) recently reviewed. This review consists of a side by side comparison of the grant application with the corresponding IACUC protocol(s) to ensure that the animal work outlined in the grant application is covered in the IACUC protocols. Our review of the grant application and the IACUC protocols is a regulatory requirement and is intended to ensure compliance with NIH regulations. We are extremely pleased to inform you that your grant application and IACUC protocol were congruent. **This protocol provided covers all animal work to be conducted under grant:**


Designated Official Signature: N/A

Date: N/A

APPROVED -- The IACUC finds that the protocol/renewal/addendum meets with the guidelines and standards for humane animal care and use as set forth by the New York Blood Center, the Animal Welfare Act and the NIH Guide for the Care and Use of Laboratory Animals. The Principal Investigator is given approval for animal purchase, board and use for the research described herein.

MODIFICATIONS TO SECURE APPROVAL– A decision of APPROVAL is deferred until after the Principal Investigator has submitted a written response to the specific recommendations of the IACUC

NOT APPROVED - The protocol "renewal" and ,or "addendum" does not meet the above guidelines and standards. Significant revision and re submission to the IACUC is required. Animals may not be purchased, boarded or used for research until IACUC approval is attained.


Xiuli An, Ph.D
Chairperson, IACUC


8, 21, 2019
Date



Institutional Biosafety Committee
310 East 67th Street
New York, New York 10065
212-570-3034

MEMORANDUM

TO: Lanying Du, Ph.D.
Head, Viral Immunology

FROM: John Svagr 
Biosafety Officer, Institutional Biosafety Committee

DATE: April 24, 2019

RE: **Protocol 21-SJ1-98:**
Structure, function & immunogenicity of HIV gp41 core

The above referenced protocol was presented to the IBC full board for review. Please note your protocol has been approved having met the requested modifications at the status of "BSL2". This approval is valid until the next IBC Meeting. Thank you.